HK1211043A1 - Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection c5 - Google Patents

Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection c5

Info

Publication number
HK1211043A1
HK1211043A1 HK15111863.4A HK15111863A HK1211043A1 HK 1211043 A1 HK1211043 A1 HK 1211043A1 HK 15111863 A HK15111863 A HK 15111863A HK 1211043 A1 HK1211043 A1 HK 1211043A1
Authority
HK
Hong Kong
Prior art keywords
inhibition
treatment
acute vascular
activation
complement
Prior art date
Application number
HK15111863.4A
Other languages
English (en)
Chinese (zh)
Inventor
Bill N C Sun
Michael S C Fung
Cecily Sun
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of HK1211043A1 publication Critical patent/HK1211043A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK15111863.4A 2000-10-10 2015-12-02 Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection c5 HK1211043A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23930900P 2000-10-10 2000-10-10

Publications (1)

Publication Number Publication Date
HK1211043A1 true HK1211043A1 (en) 2016-05-13

Family

ID=22901599

Family Applications (3)

Application Number Title Priority Date Filing Date
HK10102519.6A HK1134508A1 (en) 2000-10-10 2010-03-10 Antibodies against c5 inhibiting type ii endothelial cell activation ii c5
HK15111863.4A HK1211043A1 (en) 2000-10-10 2015-12-02 Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection c5
HK16113934A HK1225741A1 (zh) 2000-10-10 2016-12-07 用於治療和預防異種移植或急性血管排斥反應的補體c5激活的抑制

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK10102519.6A HK1134508A1 (en) 2000-10-10 2010-03-10 Antibodies against c5 inhibiting type ii endothelial cell activation ii c5

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16113934A HK1225741A1 (zh) 2000-10-10 2016-12-07 用於治療和預防異種移植或急性血管排斥反應的補體c5激活的抑制

Country Status (11)

Country Link
US (1) US6534058B2 (xx)
EP (5) EP1325033B1 (xx)
AT (1) ATE449791T1 (xx)
AU (1) AU2001296594A1 (xx)
CA (1) CA2424379C (xx)
DE (1) DE60140618D1 (xx)
DK (1) DK1325033T3 (xx)
ES (2) ES2483991T3 (xx)
HK (3) HK1134508A1 (xx)
PT (1) PT1325033E (xx)
WO (1) WO2002030985A2 (xx)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20021527A1 (it) * 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
WO2004050111A2 (en) * 2002-12-02 2004-06-17 Resistentia Pharmaceuticals Ab Methods and materials for treating inflammatory conditions using a polypeptide comprising a self-c5 amino acid segment and a non-self amino acid segment
US20070123466A1 (en) * 2003-05-13 2007-05-31 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of treating recurrent miscarriages
ATE498010T1 (de) * 2004-03-01 2011-02-15 Immune Disease Inst Inc Natürliche igm-antikörper und inhibitoren davon
EP2338511A3 (en) 2004-05-14 2012-07-25 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
AU2013200223B2 (en) * 2005-11-04 2015-08-20 Genentech, Inc. Use of Complement Pathway Inhibitors to Treat Ocular Diseases
JP2009514888A (ja) * 2005-11-04 2009-04-09 ジェネンテック・インコーポレーテッド 眼疾患を処置するための補体経路の阻害剤の使用
EP1988882B1 (en) * 2006-03-02 2014-12-17 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
EP3167888B1 (en) 2006-03-15 2024-05-01 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
DK3056568T3 (da) 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
CA2662480C (en) 2006-09-05 2016-11-08 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
TW201534620A (zh) * 2006-11-02 2015-09-16 Genentech Inc 人類化之抗-因子ｄ抗體及其用途
PL2148691T3 (pl) 2007-02-05 2015-12-31 Apellis Pharmaceuticals Inc Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
DK2275443T3 (en) 2008-04-11 2016-02-08 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of repetitively binding to two or more antigen molecules
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
AU2014201433B2 (en) * 2008-08-05 2016-05-26 Novartis Ag Compositions and methods for antibodies targeting complement protein C5
CN102170906B (zh) * 2008-08-05 2014-07-30 诺华股份有限公司 靶定补体蛋白c5的抗体的组合物和方法
TR201910848T4 (tr) 2009-02-13 2019-08-21 Immunomedics Inc İntraselüler olarak ayrilabi̇len bi̇r bağa sahi̇p i̇mmunokonjugatlar
EP2478110B1 (en) 2009-09-16 2016-01-06 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
IN2012DN03354A (xx) 2009-12-02 2015-10-23 Immunomedics Inc
KR102385507B1 (ko) 2010-11-30 2022-04-12 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
CN107115526A (zh) 2011-05-02 2017-09-01 免疫医疗公司 用于小体积施用的同种异型选择的抗体的超滤浓缩
CA2840270C (en) 2011-06-22 2023-09-26 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
EP3330288A1 (en) 2011-12-21 2018-06-06 Novartis AG Compositions and methods for antibodies targeting factor p
US9808502B2 (en) 2012-02-20 2017-11-07 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement C5
CN109513003A (zh) 2012-08-14 2019-03-26 Ibc药品公司 用于治疗疾病的t-细胞重定向双特异性抗体
TW201418707A (zh) * 2012-09-21 2014-05-16 Alexion Pharma Inc 補體組分ｃ５拮抗劑之篩選分析
CN105051057B (zh) 2012-11-15 2019-11-19 阿佩利斯制药公司 细胞反应性的、长效的或靶向的坎普他汀类似物及相关组合物和方法
KR20230078823A (ko) 2012-12-13 2023-06-02 이뮤노메딕스, 인코오포레이티드 개선된 효능 및 감소된 독성을 위한 항체 및 sn-38의 면역컨쥬게이트의 투약
BR112015018438A2 (pt) * 2013-01-31 2017-07-18 Seoul Nat Univ R&Db Foundation anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
US10308687B2 (en) 2013-03-15 2019-06-04 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
EA201690213A1 (ru) 2013-08-12 2016-07-29 Дженентек, Инк. Композиции и способ лечения связанных с комплементом состояний
PT3038633T (pt) 2013-08-28 2021-01-14 Ipc Res Llc Polipéptidos estáveis que se ligam ao complemento humano c5
CN117964710A (zh) 2013-08-28 2024-05-03 阿菲博迪公司 具有突变的支架的结合多肽
MX2016010683A (es) 2014-02-21 2017-05-11 Ibc Pharmaceuticals Inc Terapia para tratar enfermedades mediante la induccion de respuesta inmune de las células que expresan trop-2.
US9139649B2 (en) 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
AU2015253042A1 (en) 2014-05-01 2016-10-20 Genentech, Inc. Anti-factor D antibody variants and uses thereof
US9580495B2 (en) 2014-06-24 2017-02-28 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
WO2016057398A1 (en) 2014-10-07 2016-04-14 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
SG10201710322VA (en) 2014-12-19 2018-02-27 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
EP3247723A1 (en) 2015-01-22 2017-11-29 Chugai Seiyaku Kabushiki Kaisha A combination of two or more anti-c5 antibodies and methods of use
JP6746845B2 (ja) 2015-04-22 2020-08-26 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 循環ｔｒｏｐ−２陽性癌細胞の単離、検出、診断及び／または特徴付け
EP3313443B9 (en) 2015-06-25 2023-10-04 Immunomedics, Inc. Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP3316885B1 (en) 2015-07-01 2021-06-23 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
CA3001128A1 (en) 2015-10-07 2017-04-13 Apellis Pharmaceuticals, Inc. Use of long-acting compstatin analog for treating a complement-mediated eye disorder
TW201718014A (zh) 2015-10-12 2017-06-01 諾華公司 C5抑制劑於移植相關微血管病之用途
WO2017075252A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
JP7102353B2 (ja) 2016-06-14 2022-07-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｃ５抗体及びそれらの使用
IL264626B (en) 2016-08-05 2022-07-01 Chugai Pharmaceutical Co Ltd A preparation for the prevention or treatment of diseases related to il-8
MY201148A (en) 2017-01-31 2024-02-07 Hoffmann La Roche A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
CA3059304A1 (en) 2017-04-07 2018-10-11 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
SG11202004662RA (en) 2017-12-13 2020-06-29 Regeneron Pharma Anti-c5 antibody combinations and uses thereof
US20210301004A1 (en) 2018-08-01 2021-09-30 Chugai Seiyaku Kabushiki Kaisha A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
WO2021019036A1 (en) 2019-07-31 2021-02-04 F. Hoffmann-La Roche Ag Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab
AU2020319677A1 (en) 2019-07-31 2022-01-06 F. Hoffmann-La Roche Ag Dosage and administration regimen for the treatment or prevention of C5-related diseases by the use of the anti-C5 antibody Crovalimab
WO2021067526A1 (en) 2019-10-02 2021-04-08 Alexion Pharmaceuticals, Inc. Complement inhibitors for treating drug-induced complement-mediated response
CN111171149B (zh) * 2020-02-23 2021-09-07 北京康普美特创新医药科技有限责任公司 一种抗补体c5分子的人源化单链抗体及其应用
EP4150338A1 (en) 2020-05-15 2023-03-22 Alexion Pharmaceuticals, Inc. Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease
CN114149501B (zh) * 2020-12-11 2023-05-26 天士力生物医药股份有限公司 抗c5抗体及其应用
EP4342497A1 (en) 2021-05-10 2024-03-27 Kawasaki Institute of Industrial Promotion Antibody having reduced binding affinity for antigen

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5506247A (en) 1988-04-15 1996-04-09 T Cell Sciences, Inc. Compounds that inhibit complement and/or suppress immune activity
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US5679546A (en) 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
EP0751787B1 (en) * 1994-03-23 2005-01-12 Alexion Pharmaceuticals, Inc. Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
US5546808A (en) 1994-09-06 1996-08-20 Harris Instrument Corporation Apparatus and method for binocular measurement system
US5463564A (en) 1994-09-16 1995-10-31 3-Dimensional Pharmaceuticals, Inc. System and method of automatically generating chemical compounds with desired properties
CA2248772C (en) 1996-03-13 2007-06-12 John D. Lambris Novel peptides which inhibit complement activation
AU7466998A (en) 1997-04-14 1998-11-11 Byron E. Anderson Method and material for inhibiting complement
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
AU756490B2 (en) 1997-08-26 2003-01-16 Abgenix, Inc. A process for inhibiting complement activation via the alternative pathway

Also Published As

Publication number Publication date
EP2113516A1 (en) 2009-11-04
CA2424379C (en) 2013-10-01
EP3031827A1 (en) 2016-06-15
EP2113516B1 (en) 2014-05-21
AU2001296594A1 (en) 2002-04-22
EP2896631A1 (en) 2015-07-22
ES2483991T3 (es) 2014-08-08
DE60140618D1 (de) 2010-01-07
EP1325033B1 (en) 2009-11-25
ATE449791T1 (de) 2009-12-15
US20020041875A1 (en) 2002-04-11
WO2002030985A2 (en) 2002-04-18
CA2424379A1 (en) 2002-04-18
EP2281840A2 (en) 2011-02-09
HK1225741A1 (zh) 2017-09-15
HK1134508A1 (en) 2010-04-30
WO2002030985A3 (en) 2002-12-05
US6534058B2 (en) 2003-03-18
EP2281840A3 (en) 2012-05-23
DK1325033T3 (da) 2010-04-06
EP1325033A2 (en) 2003-07-09
ES2333775T3 (es) 2010-03-01
PT1325033E (pt) 2010-04-15

Similar Documents

Publication Publication Date Title
HK1225741A1 (zh) 用於治療和預防異種移植或急性血管排斥反應的補體c5激活的抑制
CY1108663T1 (el) Αναστολεις της ενεργοποιησης συμπληρωματος
NO2006008I1 (no) Natalizumab, anti alfa-4 integrin humanized monoclonal antibody
WO2001070818A8 (en) Anti-c2/c2a inhibitors of complement activation
WO1998057994A3 (en) Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
NZ611387A (en) Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment
KR960704576A (ko) CD40에 대한 항체(Antibodies to CD40)
NZ596723A (en) Human antibodies that bind human il-12 and methods for producing
NZ568403A (en) CD20-specific antibodies and methods of employing same
WO2004032868A3 (en) Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
HK1071304A1 (en) Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b
PT2067788E (pt) Bibliotecas de fragmentos fab e métodos para a sua utilização
EP1112085A4 (en) ANTI-THROMBOTIC AGENT AND HUMANIZED MONOCLONAL ANTIBODY AGAINST VON-WILLEBRAND FACTOR
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
DE69922834D1 (de) Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation
UA41984C2 (uk) Спосіб інгібування утворення тромбів у людини (варіанти), спосіб лікування людини для зниження у людини небезпеки постхірургічних тромботичних ускладнень (варіанти),спосіб лікування тромботичного судинного захворювання у людини (варіанти), фармацевтична композиція, що містить некон'юговане антифібринове моноклональне антитіло мн-1, фармацевтична композиція, що містить некон'югований фрагмент або похідне антифібринового моноклонального антитіла мн-1, набір для лікування людини, що потребує інгібування утворення тромбу
WO2002094194A3 (en) Compositions and methods for inhibiting metastasis
IL139571A0 (en) A humanized antibody that binds to verotoxin, methods for the production thereof and pharmaceutical compositions containing the same
WO2002094376A3 (en) Compositions and methods for promoting or inhibiting ndpk